Details About Generic Salt ::  Ciproflo

Main Medicine Class:: Antibiotic,Fluoroquinolone   

(sip-ROW-FLOX-uh-sin)

Cipro, Cipro IV, Ciloxan

Class: Antibiotic/Fluoroquinolone

Drugs Class ::

 Action Interferes with microbial DNA synthesis.

Indications for Drugs ::

 Indications Treatment of infections of lower respiratory tract, skin and skin structure, bone and joint, urinary tract, gonorrhea, chancroid, and infectious diarrhea caused by susceptible strains of specific organisms; typhoid fever; uncomplicated cervical and urethral gonorrhea; females with acute uncomplicated cystitis; acute sinusitis; nosocomial pneumonia; chronic bacterial prostatitis; complicated intra-abdominal infections; reduce incidence or progression of inhalational anthrax following exposure to aerosolized Organism: Bacillus anthracis. Ophthalmic use: Treatment of corneal ulcers and conjunctivitis due to susceptible organisms. Unlabeled use(s): Treatment of pulmonary exacerbations associated with cystic fibrosis; management of malignant external otitis, “traveler’s” diarrhea, mycobacterial infections.

Drug Dose ::

 Route/Dosage

Urinary Tract Infections

ADULTS: PO 250 to 500 mg or IV 200 to 400 mg q 12 hr.

Respiratory Tract; Bone and Joint; Skin and Skin Structure Infections

ADULTS: PO 500 to 750 mg or IV 400 mg q 12 hr.

Infectious Diarrhea

ADULTS: PO 500 mg q 12 hr.

Inhalational Anthrax (Postexposure)

ADULTS: PO 500 mg q 12 hr for 60 days or IV 400 mg q 12 hr for 60 days. CHILDREN: PO 15 mg/kg/dose (max 500 mg dose) q 12 hr for 60 days or IV 10 mg/kg/dose (max 400 mg dose) q 12 hr for 60 days.

Ocular Infections

ADULTS: Topical Acute infection: 1 to 2 drops q 15 to 30 min; Moderate infection: 1 to 2 drops 4 to 6 times daily.

Typhoid Fever

ADULTS: PO 500 mg q 12 hr.

Urethral/Cervical Gonococcocal Infections

ADULTS: PO 250 mg as a single dose.

Acute Uncomplicated Cystitis

ADULTS: PO 100 mg q 12 hr.

Acute Sinusitis; Chronic Bacterial Prostatitis; Complicated Intra-Abdominal Infections

ADULTS: PO 500 mg q 12 hr. IV 400 mg q 12 hr.

Nosocomial Pneumonia

ADULTS: IV 400 mg q 8 hr.

Chancroid

ADULTS: PO 500 mg bid.

Gonorrhea, Disseminated

ADULTS: Initial treatment IV 500 mg q 12 hr for 24 to 48 hr, then PO 500 mg bid for 7 days.

Gonorrhea, Uncomplicated

PO 500 mg as a single dose plus azithromycin 1 g (single dose) or doxycycline 100 mg bid for 7 days.

Contraindication ::

 Contraindications Hypersensitivity to fluoroquinolones or quinolones; tendonitis or tendon rupture associated with quinolone use. Ophthalmic use: Epithelial herpes simplex keratitis; vaccinia; varicella; fungal disease of ocular structure; mycobacterial infections of eye.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use in children < 18 yr. Convulsions: CNS stimulation can occur; use with caution in patients with known or suspected CNS disorders. Renal function impairment: Reduced clearance may occur; adjust dose downward accordingly in patients with creatinine clearance < 50 ml/min. Refer to manufacturer’s package insert for dose calculations. Hypersensitivity reactions: Serious and potentially fatal reactions have occurred. Discontinue drug if allergic reaction occurs. Pseudomembranous colitis: Consider possibility in patients with diarrhea. superinfection: Use of antibiotics may result in bacterial or fungal overgrowth. Do not use topically in deep-seated ocular infections. Photosensitivity: Moderate-to-severe reactions have occurred with some fluoroquinolones; avoid excessive sunlight and discontinue therapy if phototoxicity occurs. Crystalline precipitate: A white crystalline precipitate in superficial portion of corneal defect may occur; reaction is generally self-limiting and does not appear to affect outcome.

Drug Side Effects ::

 Adverse Reactions

CNS: Headache; restlessness. DERM: Rash. EENT: (Ophthalmic use): Lid margin crusting; foreign body sensation; itching; conjunctival hyperemia; decreased vision; sensitivity reactions (eg, transient irritation, burning, stinging, inflammation, angioneurotic edema, dermatitis). Ophthalmic use may produce same adverse effects seen with systemic use. GI: Diarrhea; nausea; vomiting; abdominal pain/discomfort. OTHER: Abnormal taste; photosensitivity.

Drug Mode of Action ::  

 Action Interferes with microbial DNA synthesis.

Drug Interactions ::

 Interactions

Antacids, iron salts, zinc salts, sucralfate, didanosine: May decrease oral absorption of fluoroquinolone. Stagger administration times. Anticoagulants: May increase effect of warfarin; monitor prothrombin time. Antineoplastic agents: Fluoroquinolone serum levels may be decreased by cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mitoxantrone, and vincristine. Azlocillin: Decreased clearance of ciprofloxacin. Caffeine: Clearance of caffeine is reduced. Cimetidine: May interfere with fluoroquinolone elimination and increase effect. Cyclosporine: Nephrotoxic effects of cyclosporine may be increased; monitor renal function. Probenecid: Decreased ciprofloxacin renal clearance. Theophylline: Decreased clearance and increased plasma levels of theophylline may result in toxicity; monitor theophylline level.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Monitor I&O.
• Monitor for signs of anaphylaxis (eg, pharyngeal or facial edema, dyspnea, urticaria, itching, hypotension).
• Assess patency of IV site and observe for signs of phlebitis frequently during therapy.
• Monitor signs of infection throughout course of treatment.
• Notify physician if symptoms of pseudomembranous colitis occur (eg, loose or foul-smelling stools) or if symptoms of CNS stimulation occur (eg, tremor, restlessness, confusion, hallucinations).

Drug Storage/Management ::

 Administration/Storage

Oral

• Give oral preparation 2 hr after meals; if necessary it may be taken with food. Avoid concurrent use of dairy products, antacids, iron- or zinc-containing products, such as multivitamins, with ciprofloxacin.

IV

• For IV infusion, dilute before administration to final concentration of 1 to 2 mg/mL.
• Refrigerate or store at room temperature and use within 14 days.
• Infuse over 60 min in large vein to reduce risk of venous irritation.

Ophthalmic

• For ophthalmic application, have patient tilt head back, pull lower lid out to make pocket, then place medication in conjunctival sac. Then, without touching patient’s eyes, close them. Apply light finger pressure on lacrimal sac for 1 min following application.

Drug Notes ::

 Patient/Family Education

• Instruct patient to drink sufficient fluids to ensure adequate urinary output.
• Inform patient that tablets may be taken orally without regard to meals, although manufacturer recommends 2-hr interval after meals.
• Caution patient to avoid exposure to sunlight, and to use sunscreens or protective clothing until tolerance is determined.
• Instruct patient to report signs of bacterial or fungal overgrowth (eg, black, furry appearance of tongue, vaginal itching or discharge, loose or foul-smelling stools).
• Caution patient that drug may cause dizziness or lightheadedness, and to use caution while driving or performing other tasks requiring mental alertness.
• Caution patients against doubling a dose to “catch up” unless advised by a physician. Instruct patient to contact physician if > 1 dose is missed.
• Emphasize importance of completing entire dose regimen.
• Advise patient not to take any otc medications without consulting physician.
• Instruct patient to stop treatment and inform physician if experiencing pain, inflammation, or rupture of tendon, and to rest or refrain from exercise until diagnosis of tendonitis or tendon rupture has been excluded.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.